CD22 and non-Hodgkin lymphoma: Indeed, the incidence and severity observed in this study compare favorably to those seen in NHL patients treated with inotuzumab ozogamicin, a CD22-targeted ADC containing calicheamicin, where these events were the leading cause of serious adverse events, dose modifications, and discontinuations [24].